Given the fact that there are no specific STEAP4 inhibitors, the elucidation of the molecular mechanism by which STEAP4 affects the development of HER2+ BC could highlight novel druggable partners for more selective targeting of STEAP4 in HER2+ BC therapy. The gene discussed is ERBB2; the disease is breast cancer.